Biothera Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

EAGAN, Minn., Nov. 21, 2017 -- Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the 29^th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 11:10 a.m. Eastern Time in New York, NY.  Mr. Labinger will provide an overview of Biothera Pharmaceuticals and an update on its clinical development plans in oncology.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held clinical stage immuno-oncology company developing Imprime PGG, a Phase 2 cancer immunotherapy that has been shown in preclinical studies to enhance the efficacy of anti-cancer immune responses in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenic antibodies.  Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA^® (pembrolizumab), Merck’s anti-PD-1 antibody, in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer.  This therapeutic combination is also being evaluated in a Big Ten Cancer Research Consortium Phase 1b/2 trial for patients with non-small cell lung cancer.

Contact:
David Walsh
Biothera Pharmaceuticals, Inc.
651-256-4606
[email protected]